Last reviewed · How we verify
Clarity Pharmaceuticals Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 64Cu-SAR-bisPSMA | 64Cu-SAR-bisPSMA | phase 3 | Radiopharmaceutical; PET imaging agent | PSMA (prostate-specific membrane antigen) | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GE Healthcare · 1 shared drug class
- Queen's Medical Center · 1 shared drug class
- Radiomedix, Inc. · 1 shared drug class
- Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class
- UMC Utrecht · 1 shared drug class
- University of Colorado, Denver · 1 shared drug class
- University of Saskatchewan · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Clarity Pharmaceuticals Ltd:
- Clarity Pharmaceuticals Ltd pipeline updates — RSS
- Clarity Pharmaceuticals Ltd pipeline updates — Atom
- Clarity Pharmaceuticals Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Clarity Pharmaceuticals Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clarity-pharmaceuticals-ltd. Accessed 2026-05-16.